

IP Law Update

Summer 2017

Welcome to the summer 2017 edition of the Withers & Rogers IP Law Update. This e-newsletter provides a round-up of our articles covering some of the most significant intellectual property cases that have been decided in the UK and Europe in the past year.

It is a year on from the tumultuous summer of 2016 in which the UK narrowly voted to leave the European Union. Now that the famous "Article 50" has been triggered, negotiations between the UK and the EU have started with both sides hoping for an amicable divorce. On the ground, however, nothing much has changed in the day-to-day business of IP litigation.

Likewise the Unitary Patent project continues to rumble away, getting ever closer despite various spanners being thrown in the works. The latest of these is a legal challenge brought in the German Constitutional Court. The UPC Preparatory Committee now expects the so-called "sunrise" period to begin in early 2018 and to last 6-8 months before the system comes fully into effect.

As is often the case, the pharmaceutical and telecommunications industries account for much of the case law we've reported on over the last year. The Supreme Court judgment in the

Eli Lilly v Actavis saga is the most far-reaching decision for some time and could have implications for companies in all sectors. In this publication you will also find the courts have clarified the always prickly issue of how to interpret numerical ranges, and have commented on how to determine licensing terms that are fair, reasonable and non-discriminatory, known as "FRAND".

An overview of the trade mark cases we have reported shows that the huge increase in internet shopping is having a knock-on effect on the use, and sometimes abuse, of trade marks. This trend seems likely to continue.

I hope you find this issue of our IP Law Update interesting and informative. If you have any questions please do not hesitate to contact me or your usual W&R contact.



Elizabeth Swan Editor and Senior Associate eswan@withersrogers.com



Inside...

Patent Cases

Eli Lilly reigns Supreme

Supplementary Protection Certificates

SPCs can be used for compounds hidden within generic claims

Trade Mark Cases

The final twist: Rubik's Cube trade mark declared invalid by EU Cour

And much more!

Patent Cases




Sound Plausible? How much data does your patent application really need to include?

By Helen Henderson

T 488/16

A recent decision by the EPO to revoke Bristol-Myers Squibb's European patent for the blockbuster anti-cancer drug dasatinib (Sprycel®) caused ripples through the pharmaceutical industry The reasoning behind this decision has now been published by the EPO and provides some useful guidance as to what is required to establish that a technical effect is plausibly achieved.





Next Page: Patent Cases

Patent Cases





Eli Lilly reigns Supreme

By Elizabeth Swan and Nicholas Jones

Eli Lilly and Company v Actavis UK Limited and others [2017] UKSC 48

It is not often that a Supreme Court decision on IP comes along, and even less often one that has very significant things to say about the way we determine the scope of patent claims. This decision is relevant to all sectors and brings forth a new approach to considering claim scope, which is arguably more akin to the US "doctrine of equivalents" than to previous UK case law. It also sets out clear rules on when the prosecution history can legitimately be used to guide claim interpretation. If there is only one decision you read this year, I recommend you make it this one!

Read More...





Court of Appeal provides clarification "about" numerical values

By Bruce Dean

Napp Pharmaceutical Holdings Limited v Dr Reddy's Laboratories (UK) Ltd & Anor [2016] EWCA Civ 1053

The interpretation of numerical values is, of course, critical for patent infringement and has been the subject of many court cases. In this case it was up to the court to interpret the term "about 10%". The Court of Appeal agreed with the High Court that in this case it was appropriate to interpret the figure to the nearest whole number, such that the term "about 10%" covers values in the range of 9% to 11%. This is a useful guide for claim interpretation and should be borne in mind by those drafting patent applications.

Read More...



Next Page: SPCs

Supplementary Protection Certificates





SPCs can be used for compounds hidden within generic claims

By Andrew Evitt

Sandoz Ltd & Anor v G.D. Searle LLC & Anor [2017] EWHC 987

SPCs have, understandably, been the subject of a lot of case law. The many rulings from the CJEU can make confusing reading. Here the High Court has good news for SPC owners in confirming that an SPC is allowable for a compound that is not specifically identified in a patent but (a) where there is a generic claim that covers the product and (b) where the product embodies the technical advance of the claim.


Read More...



Trade Marks







Next Page: Trade Marks

Trade Marks




The final twist: Rubik's Cube trade mark declared invalid by EU Court

By Mark Caddle

C-30/15 Simba Toys GmbH & Co. KG v EUIPO

Interestingly the interplay between patents and trade marks was highlighted in this case where the CJEU confirmed that the technical function of a product is relevant for assessment of the essential characteristics of the shape. This meant that the way that the Rubik's cube works, with rotating internal elements, is relevant to the assessment of trade mark suitability.







Contact Us

London

4 More London Riverside London SE1 2AU UK

Tel: +44 (0) 20 7940 3600 Fax: +44 (0) 20 7378 9680

Midlands

Nicholas Wilson House Dormer Place, Leamington Spa Warwickshire CV32 5AE UK

Tel: +44 (0) 1926 310 700 Fax: +44 (0) 1926 335 519

Munich

Steinerstr. 15 / building A D-81369 Munich Germany

Tel: +49 89 502224020

Bristol

1 Redcliff Street Bristol BS1 6NP United Kingdom Tel: +44 117 925 3030 Fax: +44 117 925 3530

Sheffield

Derwent House, 150 Arundel Gate Sheffield S1 2FN UK

Tel: +44 (0) 114 273 3400 Fax: +44 (0) 114 275 5788